Press release

Novugen Pharma (USA) LLC Launches ANDA Approved Midodrine 2.5mg, 5mg & 10mg

Novugen Pharma (USA) LLC has launched Midodrine 2.5mg, 5mg and 10mg in the U.S. upon the approval from ANDA by FDA. Novugen's Midodrine will be manufactured in Malaysia by Novugen Pharma Sdn. Bhd. Midodrine is indicated for the treatment of symptomatic orthostatic hypotension, a condition defined as a sudden drop in blood pressure upon standing from a sitting or supine position.

Princeton, NJ November 07, 2023 --(PR.com)-- Novugen Pharma (USA) LLC has launched their second product in the U.S. market, Midodrine 2.5mg, 5mg and 10mg upon the approval from Abbreviated New Drug Application (ANDA) by Food and Drug Administration (FDA). The first product that was launched by the company in the U.S. was Abiraterone 250mg and 500mg tablets.

Midodrine is indicated for the treatment of symptomatic orthostatic hypotension, a condition defined as a sudden drop in blood pressure upon standing from a sitting or supine position. This drop in blood pressure can cause dizziness and escalates the risk of fainting, falling, cardiovascular disease, dementia, depression and in some cases, death. It was reported that one in five adults over the age of 60 have orthostatic hypotension* and can be up to six in ten amongst the institutionalized elderly.**

Novugen’s Midodrine will be ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner
Trending

More to read